Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters.
Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters.
复制标题
基于vsv的仓鼠单剂量COVID-19疫苗接种优化
DOI：
10.3389/fimmu.2021.788235
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Marzi A
中科院分区：
文献类型：
--
作者：
O'Donnell KL;Clancy CS;Griffin AJ;Shifflett K;Gourdine T;Thomas T;Long CM;Furuyama W;Marzi A
持续的COVID-19大流行对人类健康、经济稳定和社会规范造成了全球性影响。病毒变异的出现引起了人们对现有疫苗效力的关注，并突出表明继续需要开发高效、快速和具有成本效益的疫苗。在这里，我们证明了两种基于水疱性口炎病毒（VSV）的编码SARS-CoV-2刺突蛋白的疫苗单独（VSV- sars2）或与埃博拉病毒糖蛋白（VSV- sars2 - ebov）联合的免疫原性和保护效果。鼻内接种的仓鼠在肺部表现出早期的CD8+ T细胞反应和更大的抗原特异性IgG反应，而肌内接种的仓鼠则表现出早期的CD4+ T细胞和NK细胞反应。鼻内疫苗接种在10天内产生保护作用，当受到三种不同的SARS-CoV-2变体的攻击时，仓鼠没有表现出肺炎的临床症状。这一数据表明，基于vsv的疫苗是可行的单剂量、速效候选疫苗，可以预防COVID-19。
The ongoing COVID-19 pandemic has resulted in global effects on human health, economic stability, and social norms. The emergence of viral variants raises concerns about the efficacy of existing vaccines and highlights the continued need for the development of efficient, fast-acting, and cost-effective vaccines. Here, we demonstrate the immunogenicity and protective efficacy of two vesicular stomatitis virus (VSV)-based vaccines encoding the SARS-CoV-2 spike protein either alone (VSV-SARS2) or in combination with the Ebola virus glycoprotein (VSV-SARS2-EBOV). Intranasally vaccinated hamsters showed an early CD8+ T cell response in the lungs and a greater antigen-specific IgG response, while intramuscularly vaccinated hamsters had an early CD4+ T cell and NK cell response. Intranasal vaccination resulted in protection within 10 days with hamsters not showing clinical signs of pneumonia when challenged with three different SARS-CoV-2 variants. This data demonstrates that VSV-based vaccines are viable single-dose, fast-acting vaccine candidates that are protective from COVID-19.